Depo-Provera and Meningioma Risk: What Women Need to Know About the 150 mg Dose and Emerging Litigation
Link Between High-Dose Birth Control Injections and Brain Tumors Spurs Legal Action Nationwide
Depo-Provera (medroxyprogesterone acetate) is a widely prescribed injectable birth control option that offers a convenient alternative to daily pills. However, growing scientific evidence has linked long-term use of high-dose Depo-Provera injections (150 mg) to the development of meningiomas, a type of brain tumor that can cause serious, life-altering complications.
As lawsuits against Depo-Provera manufacturers continue to emerge nationwide, women who received repeated injections may now have legal options to pursue compensation.
Understanding Depo-Provera and the 150 mg Dose
The standard Depo-Provera injection contains 150 milligrams of medroxyprogesterone acetate, a synthetic form of progesterone. This birth control shot is administered every 12 to 13 weeks to prevent ovulation and pregnancy.
Depo-Provera is sold under the brand Depo-Provera CI and in generic versions manufactured and distributed by:
-
Pharmacia & Upjohn Company LLC (Pfizer subsidiary)
-
Greenstone LLC
-
A-S Medication Solutions
-
Prasco Laboratories
-
Preferred Pharmaceuticals Inc.
While many women used Depo-Provera without immediate issues, recent studies show that cumulative exposure from repeated 150 mg injections, particularly four or more doses in a 12-month period, may significantly increase the risk of developing meningioma brain tumors.
Meningioma: A Serious Brain Tumor Risk Linked to Depo-Provera
Meningiomas are tumors that form in the meninges, the protective membranes surrounding the brain and spinal cord. Although often benign, these tumors can cause severe neurological complications depending on their size and location.
Common meningioma symptoms include:
-
Chronic headaches
-
Vision problems
-
Memory loss or confusion
-
Seizures
-
Weakness or numbness
Medical research suggests that prolonged exposure to synthetic progesterone, such as medroxyprogesterone acetate, increases the risk of progesterone receptor–positive meningiomas, particularly with long-term, high-dose use.
International regulators have taken notice. In France, health authorities issued warnings and updated product labeling to reflect the meningioma risk associated with repeated 150 mg Depo-Provera injections.
Legal Action Against Depo-Provera Manufacturers
Women diagnosed with meningiomas after long-term Depo-Provera use are now filing product liability lawsuits alleging:
-
Failure to warn patients and healthcare providers of known risks
-
Negligent marketing of a high-risk hormonal drug
-
Concealment of safety data related to brain tumor risks
Most claims involve women who received at least 600 mg of medroxyprogesterone acetate (four injections) within a year or longer, resulting in dangerous hormone accumulation.
How Mancini Law Group P.C. Can Help
At Mancini Law Group P.C., we are actively investigating Depo-Provera brain tumor lawsuits on behalf of women who:
-
Received four or more 150 mg Depo-Provera injections
-
Used Depo-Provera for 12 months or longer
-
Were later diagnosed with a meningioma
With over 30 years of experience in pharmaceutical and product liability litigation, our attorneys understand the devastating impact of a brain tumor diagnosis and fight aggressively to hold negligent drug manufacturers accountable.
Compensation May Include
Victims of Depo-Provera–related meningiomas may be entitled to compensation for:
-
Medical expenses (surgery, MRIs, neurological care)
-
Lost wages and diminished earning capacity
-
Pain and suffering
-
Long-term neurological impairment or disability
Schedule a Free Consultation Today
If you or a loved one were diagnosed with a meningioma after repeated Depo-Provera 150 mg injections, time may be limited to take legal action.
Call Mancini Law Group P.C. at 773-745-1909 for a free, confidential consultation.
Your need for justice is our passion for justice.